Yeast Infections After Haematopoietic Stem Cell Transplantation

  • Jason A. Trubiano
  • Sharon C.-A. Chen
  • Monica A. Slavin
Chapter

Abstract

Invasive fungal disease (IFD) caused by yeasts and yeast-like pathogens complicates both autologous and allogeneic haematopoietic stem cell transplantation (HSCT). Epidemiology varies according to geographic location and antifungal prophylaxis and treatment practices. Invasive candidiasis (IC), including bloodstream infection (candidemia) and deep-seated tissue infection, continues to be the most common yeast infection after HSCT. Risk factors, epidemiology, impact of antifungal prophylaxis, diagnostic approaches including non-culture-based tests and emergence of azole and echinocandin resistance in Candida species are discussed. Risks for, timing of onset after HSCT and treatments for IC as well as infections due to rare and endemic yeasts such as Cryptococcus, Rhodotorula, Trichosporon and Coccidiodes are described.

Keywords

Candida disease Cryptococcus Trichosporon Antifungal treatment Antifungal resistance Haematopoietic stem cell transplantation 

References

  1. 1.
    Chen SC, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J. 2014;44(12b):1315–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007). Cancer. 2009;115(20):4745–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. 2012;50(1):50–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28(5):1071–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Ananda-Rajah MR, Cheng A, Morrissey CO, Spelman T, Dooley M, Neville AM, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother. 2011;55(5):1953–60.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.PubMedCrossRefGoogle Scholar
  7. 7.
    Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20(1):O50–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, et al. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 2015;61:324–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Jantunen E, Nihtinen A, Volin L, Juvonen E, Parkkali T, Ruutu T, et al. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. Bone Marrow Transplant. 2004;34(10):891–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Chaaban S, Wheat LJ, Assi M. Cryptococcal meningitis post autologous stem cell transplantation. Transpl Infect Dis. 2014;16(3):473–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27(12):1644–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41(7):975–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother. 2010;65(5):1042–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Hsu LY, Lee DG, Yeh SP, Bhurani D, Khanh BQ, Low CY, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect. 2015;21:594.e7–11.PubMedGoogle Scholar
  16. 16.
    Hoenigl M, Strenger V, Buzina W, Valentin T, Koidl C, Wolfler A, et al. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother. 2012;67(8):2029–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis. 2002;34(5):591–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Markowski J, Helbig G, Widziszowska A, Likus W, Kyrcz-Krzemien S, Jarosz U, et al. Fungal colonization of the respiratory tract in allogeneic and autologous hematopoietic stem cell transplant recipients: a study of 573 transplanted patients. Med Sci Monit. 2015;21:1173–80.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Chan TS, Gill H, Hwang YY, Sim J, Tse AC, Loong F, et al. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Ann Hematol. 2014;93(3):493–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181(1):309–16.PubMedCrossRefGoogle Scholar
  21. 21.
    Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine. 2003;82(5):309–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–63.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis. 2006;12(10):1508–16.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Trubiano JA, Leung VK, Worth LJ, Teh BW, Thursky KA, Slavin MA. Candida glabrata fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. Leuk Lymphoma. 2015;56:3442–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001;28(9):873–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Lockhart SR, Wagner D, Iqbal N, Pappas PG, Andes DR, Kauffman CA, et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011;49(7):2404–10.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation. 2005;80(6):868–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–32.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother. 2015;70:2362–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D, et al. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case–control study in Paris, France. Antimicrob Agents Chemother. 2011;55(11):5358–61.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case–control studies. Eur J Clin Microbiol Infect Dis. 2006;25(7):419–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8(3), e59373.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36(1):1–53.PubMedCrossRefGoogle Scholar
  34. 34.
    Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses. 2012;55(3):e74–84.PubMedCrossRefGoogle Scholar
  35. 35.
    De Castro N, Mazoyer E, Porcher R, Raffoux E, Suarez F, Ribaud P, et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007. Clin Microbiol Infect. 2012;18(6):E185–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Takemura H, Ohno H, Miura I, Takagi T, Ohyanagi T, Kunishima H, et al. The first reported case of central venous catheter-related fungemia caused by Cryptococcus liquefaciens. J Infect Chemother. 2015;21(5):392–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Rimek D, Haase G, Luck A, Casper J, Podbielski A. First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol. 2004;42(1):481–3.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis. 2009;48(11):1566–76.PubMedCrossRefGoogle Scholar
  39. 39.
    Caira M, Trecarichi EM, Tumbarello M, Leone G, Pagano L. Uncommon yeast infections in hematological patients: from diagnosis to treatment. Expert Rev Anti Infect Ther. 2011;9(11):1067–75.PubMedCrossRefGoogle Scholar
  40. 40.
    Fickweiler W, Aries MJ, Enting RH, Vellenga E, De Keyser J. Cryptococcal cerebellitis after chemotherapy and autologous stem cell re-infusion in a patient with multiple myeloma. J Neurol. 2009;256(1):145–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Mendpara SD, Ustun C, Kallab AM, Mazzella FM, Bilodeau PA, Jillella AP. Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplant. 2002;30(4):259–60.PubMedCrossRefGoogle Scholar
  42. 42.
    Kontoyiannis DP, Peitsch WK, Reddy BT, Whimbey EE, Han XY, Bodey GP, et al. Cryptococcosis in patients with cancer. Clin Infect Dis. 2001;32(11):E145–50.PubMedCrossRefGoogle Scholar
  43. 43.
    Miniero R, Nesi F, Vai S, De Intinis G, Papalia F, Targhetta R, et al. Cryptococcal meningitis following a thrombotic microangiopathy in an unrelated donor bone marrow transplant recipient. Pediatr Hematol Oncol. 1997;14(5):469–74.PubMedCrossRefGoogle Scholar
  44. 44.
    Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect. 2002;17(2):113–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Nachbaur D, Angelova O, Orth-Holler D, Ditlbacher A, Lackner M, Auberger J, et al. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. Eur J Haematol. 2015;94(3):258–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012;64(1):68–75.PubMedCrossRefGoogle Scholar
  47. 47.
    Corzo-Leon DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses. 2015;58(6):325–36.PubMedCrossRefGoogle Scholar
  48. 48.
    Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis. 2009;49(1):e11–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Blaes AH, Cavert WP, Morrison VA. Malassezia: is it a pulmonary pathogen in the stem cell transplant population? Transpl Infect Dis. 2009;11(4):313–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Morrison VA, Weisdorf DJ. The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant. 2000;26(6):645–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Bufill JA, Lum LG, Caya JG, Chitambar CR, Ritch PS, Anderson T, et al. Pityrosporum folliculitis after bone marrow transplantation. Clinical observations in five patients. Ann Intern Med. 1988;108(4):560–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Baker RM, Stegink RJ, Manaloor JJ, Schmitt BH, Stevens JC, Christenson JC. Malassezia pneumonia: a rare complication of parenteral nutrition therapy. JPEN J Parenter Enteral Nutr. 2015.Google Scholar
  53. 53.
    Alvarez-Perez S, Blanco JL, Pelaez T, Cutuli M, Garcia ME. In vitro amphotericin B susceptibility of Malassezia pachydermatis determined by the CLSI broth microdilution method and Etest using lipid-enriched media. Antimicrob Agents Chemother. 2014;58(7):4203–6.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Camus V, Thibault ML, David M, Gargala G, Compagnon P, Lamoureux F, et al. Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review. Mycopathologia. 2014;177(5–6):319–24.PubMedCrossRefGoogle Scholar
  55. 55.
    Picard M, Cassaing S, Letocart P, Verdeil X, Protin C, Chauvin P, et al. Concomitant cases of disseminated Geotrichum clavatum infections in patients with acute myeloid leukemia. Leuk Lymphoma. 2014;55(5):1186–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Savini V, Catavitello C, Balbinot A, Masciarelli G, Astolfi D, Pompilio A, et al. Multidrug-resistant Geotrichum capitatum from a haematology ward. Mycoses. 2011;54(6):542–3.PubMedCrossRefGoogle Scholar
  57. 57.
    Henrich TJ, Marty FM, Milner Jr DA, Thorner AR. Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. Transpl Infect Dis. 2009;11(5):458–62.PubMedCrossRefGoogle Scholar
  58. 58.
    Choi G, Meijer SL, Hazenberg MD. Disseminated bread yeast fungaemia in a baker’s wife with acute myeloid leukaemia. Br J Haematol. 2012;158(3):298.PubMedCrossRefGoogle Scholar
  59. 59.
    Cairoli R, Marenco P, Perego R, de Cataldo F. Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT. Bone Marrow Transplant. 1995;15(5):785–6.PubMedGoogle Scholar
  60. 60.
    Olver WJ, James SA, Lennard A, Galloway A, Roberts IN, Boswell TC, et al. Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. J Hosp Infect. 2002;52(4):268–72.PubMedCrossRefGoogle Scholar
  61. 61.
    Popiel KY, Wong P, Lee MJ, Langelier M, Sheppard DC, Vinh DC. Invasive Saccharomyces cerevisiae in a liver transplant patient: case report and review of infection in transplant recipients. Transpl Infect Dis. 2015;17(3):435–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Papaemmanouil V, Georgogiannis N, Plega M, Lalaki J, Lydakis D, Dimitriou M, et al. Prevalence and susceptibility of Saccharomyces cerevisiae causing vaginitis in Greek women. Anaerobe. 2011;17(6):298–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Echeverria-Irigoyen MJ, Eraso E, Cano J, Gomariz M, Guarro J, Quindos G. Saccharomyces cerevisiae vaginitis: microbiology and in vitro antifungal susceptibility. Mycopathologia. 2011;172(3):201–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45(6):1735–45.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11(2):142–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Fores R, Ramos A, Orden B, de Laiglesia A, Bautista G, Cabero M, et al. Rhodotorula species fungaemia causes low mortality in haematopoietic stem-cell transplantation. A case report and review. Mycoses. 2012;55(3):e158–62.PubMedCrossRefGoogle Scholar
  67. 67.
    Mori T, Nakamura Y, Kato J, Sugita K, Murata M, Kamei K, et al. Fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2012;14(1):91–4.PubMedCrossRefGoogle Scholar
  68. 68.
    Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses. 2011;54(4):318–24.PubMedCrossRefGoogle Scholar
  69. 69.
    Girmenia C, Pagano L, Martino B, D’Antonio D, Fanci R, Specchia G, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43(4):1818–28.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Suzuki K, Nakase K, Kyo T, Kohara T, Sugawara Y, Shibazaki T, et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Haematol. 2010;84(5):441–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis. 2014;16(2):213–24.PubMedCrossRefGoogle Scholar
  72. 72.
    Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009;69(11):1403–15.PubMedCrossRefGoogle Scholar
  73. 73.
    Mendoza N, Noel P, Blair JE. Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation. Transpl Infect Dis. 2015;17:380–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Riley DK, Galgiani JN, O’Donnell MR, Ito JI, Beatty PG, Evans TG. Coccidioidomycosis in bone marrow transplant recipients. Transplantation. 1993;56(6):1531–3.PubMedGoogle Scholar
  75. 75.
    Glenn TJ, Blair JE, Adams RH. Coccidioidomycosis in hematopoietic stem cell transplant recipients. Med Mycol. 2005;43(8):705–10.PubMedCrossRefGoogle Scholar
  76. 76.
    Haydoura S, Wallentine J, Lopansri B, Ford CD, Saad D, Burke JP. Disseminated histoplasmosis in allogeneic bone marrow transplant: a diagnosis not to be missed. Transpl Infect Dis. 2014;16(5):822–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Walsh TJ, Catchatourian R, Cohen H. Disseminated histoplasmosis complicating bone marrow transplantation. Am J Clin Pathol. 1983;79(4):509–11.PubMedCrossRefGoogle Scholar
  78. 78.
    Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis. 2002;4(3):148–51.PubMedCrossRefGoogle Scholar
  79. 79.
    Jones O, Cleveland KO, Gelfand MS. A case of disseminated histoplasmosis following autologous stem cell transplantation for Hodgkin’s lymphoma: an initial misdiagnosis with a false-positive serum galactomannan assay. Transpl Infect Dis. 2009;11(3):281–3.PubMedCrossRefGoogle Scholar
  80. 80.
    Ruiz e Resende LS, Yasuda AG, Mendes RP, Marques SA, Niero-Melo L, Defaveri J, et al. Paracoccidioidomycosis in patients with lymphoma and review of published literature. Mycopathologia. 2015;179(3–4):285–91.PubMedCrossRefGoogle Scholar
  81. 81.
    Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33(1):23–32.PubMedCrossRefGoogle Scholar
  82. 82.
    Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92.PubMedCrossRefGoogle Scholar
  83. 83.
    Cobos-Trigueros N, Morata L, Torres J, Zboromyrska Y, Soriano A, Pitart C, et al. Usefulness of time-to-positivity in aerobic and anaerobic vials to predict the presence of Candida glabrata in patients with candidaemia. J Antimicrob Chemother. 2013;68(12):2839–41.PubMedCrossRefGoogle Scholar
  84. 84.
    Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis. 2009;64(4):402–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, et al. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54(5):633–43.PubMedCrossRefGoogle Scholar
  86. 86.
    Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–70.PubMedCrossRefGoogle Scholar
  87. 87.
    De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47(6):846–54.PubMedCrossRefGoogle Scholar
  89. 89.
    Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57(Pt 3):287–95.PubMedCrossRefGoogle Scholar
  90. 90.
    Kami M, Tanaka Y, Kanda Y, Ogawa S, Masumoto T, Ohtomo K, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica. 2000;85(7):745–52.PubMedGoogle Scholar
  91. 91.
    Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 → 3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42(6):2733–41.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-beta-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46(12):1864–70.PubMedCrossRefGoogle Scholar
  93. 93.
    Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39(2):199–205.PubMedCrossRefGoogle Scholar
  94. 94.
    Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1 → 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46(3):1009–13.PubMedCrossRefGoogle Scholar
  95. 95.
    Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46(6):878–85.PubMedCrossRefGoogle Scholar
  96. 96.
    Abe M, Kimura M, Araoka H, Taniguchi S, Yoneyama A. Serum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia. Med Mycol. 2014;52(8):835–40.PubMedCrossRefGoogle Scholar
  97. 97.
    Naselli A, Faraci M, Lanino E, Morreale G, Cangemi G, Bandettini R, et al. Persistence of high-level (1,3)-beta-D-glucan after candidemia following autologous peripheral SCT in a pediatric patient. Bone Marrow Transplant. 2015;50(1):137–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Mikulska M, Furfaro E, Del Bono V, Gualandi F, Van Lint MT, Miletich F, et al. Persistence of a positive (1,3)-beta-D-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients. Clin Vaccine Immunol. 2011;18(3):518–9.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Duffner U, Abdel-Mageed A, Dahl K, Fogg G, Hester J. Serum (1 → 3)-beta-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. Bone Marrow Transplant. 2012;47(1):151–2.PubMedCrossRefGoogle Scholar
  100. 100.
    Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y. False-positive plasma (1 → 3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol. 2004;80(1):97–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med. 2013;5(182):182ra54.Google Scholar
  102. 102.
    Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Lau A, Halliday C, Chen SC, Playford EG, Stanley K, Sorrell TC. Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol. 2010;48(3):811–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49(2):665–70.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54(9):1240–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Jaye DL, Waites KB, Parker B, Bragg SL, Moser SA. Comparison of two rapid latex agglutination tests for detection of cryptococcal capsular polysaccharide. Am J Clin Pathol. 1998;109(5):634–41.PubMedCrossRefGoogle Scholar
  107. 107.
    Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol. 1994;32(7):1680–4.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4(2), e21.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7(3):375–81.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Jongwutiwes U, Sungkanuparph S, Kiertiburanakul S. Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients. Jpn J Infect Dis. 2008;61(2):111–5.PubMedGoogle Scholar
  111. 111.
    Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33(5):690–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Melcher GP, Reed KD, Rinaldi MG, Lee JW, Pizzo PA, Walsh TJ. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol. 1991;29(1):192–6.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Suwantarat N, Dalton JB, Lee R, Green R, Memon W, Carroll KC, et al. Large-scale clinical validation of a lateral flow immunoassay for detection of cryptococcal antigen in serum and cerebrospinal fluid specimens. Diagn Microbiol Infect Dis. 2015;82(1):54–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Huang HR, Fan LC, Rajbanshi B, Xu JF. Evaluation of a new cryptococcal antigen lateral flow immunoassay in serum, cerebrospinal fluid and urine for the diagnosis of cryptococcosis: a meta-analysis and systematic review. PLoS One. 2015;10(5), e0127117.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis. 2014;58(1):113–6.PubMedCrossRefGoogle Scholar
  116. 116.
    Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, Sawatwong P, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53(4):321–5.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Rivet-Danon D, Guitard J, Grenouillet F, Gay F, Ait-Ammar N, Angoulvant A, et al. Rapid diagnosis of cryptococcosis using an antigen detection immunochromatographic test. J Infect. 2015;70(5):499–503.PubMedCrossRefGoogle Scholar
  118. 118.
    Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015;78:49–54.PubMedCrossRefGoogle Scholar
  119. 119.
    McMullan BJ, Halliday C, Sorrell TC, Judd D, Sleiman S, Marriott D, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One. 2012;7(11), e49541.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Bader O, Weig M, Taverne-Ghadwal L, Lugert R, Gross U, Kuhns M. Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect. 2011;17(9):1359–65.PubMedCrossRefGoogle Scholar
  121. 121.
    Haigh J, Degun A, Eydmann M, Millar M, Wilks M. Improved performance of bacterium and yeast identification by a commercial matrix-assisted laser desorption ionization-time of flight mass spectrometry system in the clinical microbiology laboratory. J Clin Microbiol. 2011;49(9):3441.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Saracli MA, Fothergill AW, Sutton DA, Wiederhold NP. Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Med Mycol. 2015;53:736–42.PubMedCrossRefGoogle Scholar
  123. 123.
    Vella A, De Carolis E, Vaccaro L, Posteraro P, Perlin DS, Kostrzewa M, et al. Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis. J Clin Microbiol. 2013;51(9):2964–9.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Ghosh AK, Paul S, Sood P, Rudramurthy SM, Rajbanshi A, Jillwin TJ, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections. Clin Microbiol Infect. 2015;21(4):372–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Lacroix C, Gicquel A, Sendid B, Meyer J, Accoceberry I, Francois N, et al. Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. Clin Microbiol Infect. 2014;20(2):153–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532–8.PubMedCrossRefGoogle Scholar
  127. 127.
    Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother. 2010;54(12):5042–7.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Ruggero MA, Topal JE. Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy. Transpl Infect Dis. 2014;16(3):469–72.PubMedCrossRefGoogle Scholar
  129. 129.
    Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis. 2014;20(11):1833–40.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50(4):1199–203.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, et al. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. J Antimicrob Chemother. 2013;68(4):922–6.PubMedCrossRefGoogle Scholar
  132. 132.
    Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012;56(11):5898–906.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.PubMedCrossRefGoogle Scholar
  134. 134.
    Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.PubMedCrossRefGoogle Scholar
  135. 135.
    Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother. 2009;53(12):5026–34.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Bow EJ, Vanness DJ, Slavin M, Cordonnier C, Cornely OA, Marks DI, et al. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis. 2015;15:128.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52(9):3022–8.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–27.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743–6.PubMedCrossRefGoogle Scholar
  140. 140.
    Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5):451–6.PubMedCrossRefGoogle Scholar
  141. 141.
    Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014;20(11):O952–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17(4):507–15.PubMedCrossRefGoogle Scholar
  145. 145.
    Langebrake C, Rohde H, Lellek H, Wolschke C, Kroger NM. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice. Clin Transplant. 2014;28(3):286–91.PubMedCrossRefGoogle Scholar
  146. 146.
    Kabbara N, Lacroix C, Peffault de Latour R, Socie G, Ghannoum M, Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica. 2008;93(4):639–40.Google Scholar
  147. 147.
    Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25–31.PubMedCrossRefGoogle Scholar
  148. 148.
    Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60(3):613–8.PubMedCrossRefGoogle Scholar
  149. 149.
    Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54(1):184–90.PubMedCrossRefGoogle Scholar
  150. 150.
    Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Lepe-Jimenez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother. 2013;68(1):206–13.Google Scholar
  151. 151.
    Bassetti M, Merelli M, Ansaldi F, de Florentiis D, Sartor A, Scarparo C, et al. Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS One. 2015;10(5), e0127534.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Liu CY, Huang LJ, Wang WS, Chen TL, Yen CC, Yang MH, et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect. 2009;58(2):154–60.PubMedCrossRefGoogle Scholar
  153. 153.
    Khalid A, Clough LA, Symons RC, Mahnken JD, Dong L, Eid AJ. Incidence and clinical predictors of ocular candidiasis in patients with Candida fungemia. Interdiscip Perspect Infect Dis. 2014;2014:650235.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53(3):262–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med. 1989;149(10):2226–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Fernandez-Cruz A, Cruz Menarguez M, Munoz P, Pedromingo M, Pelaez T, Solis J, et al. The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. Eur J Clin Microbiol Infect Dis. 2015;34:1543–9.PubMedCrossRefGoogle Scholar
  157. 157.
    Lefort A, Chartier L, Sendid B, Wolff M, Mainardi JL, Podglajen I, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18(4):E99–109.PubMedCrossRefGoogle Scholar
  158. 158.
    Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis—a contraindication to marrow transplantation? Blood. 1994;84(8):2811–4.PubMedGoogle Scholar
  159. 159.
    Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion. 1994;34(3):226–32.PubMedCrossRefGoogle Scholar
  160. 160.
    Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case–control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004;101(12):2859–65.PubMedCrossRefGoogle Scholar
  161. 161.
    Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322.PubMedCrossRefGoogle Scholar
  162. 162.
    Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20 Suppl 3:76–98.PubMedCrossRefGoogle Scholar
  163. 163.
    Cahuayme-Zuniga L, Kontoyiannis DP. Is it safe to proceed with stem cell transplant in cancer patients treated for cryptococcal infection? A focus on recent IDSA cryptococcal guidelines. Clin Infect Dis. 2010;50(12):1687–9.PubMedCrossRefGoogle Scholar
  164. 164.
    Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis. 2013;57(4):543–51.PubMedCrossRefGoogle Scholar
  165. 165.
    Perfect JR. The impact of the host on fungal infections. Am J Med. 2012;125(1 Suppl):S39–51.PubMedCrossRefGoogle Scholar
  166. 166.
    Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol. 2008;25(3):135–40.PubMedCrossRefGoogle Scholar
  167. 167.
    Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Guillen H, Burgaleta C. Rhodotorula mucilaginosa catheter-related fungaemia in a patient with multiple myeloma. Mycoses. 2011;54(4):e214–6.PubMedCrossRefGoogle Scholar
  168. 168.
    Hofmeyr A, Slavin MA. Emerging opportunistic yeast infections in haematology patients. Leuk Lymphoma. 2006;47(9):1736–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Schoepfer C, Carla H, Bezou MJ, Cambon M, Girault D, Demeocq F, et al. Malassezia furfur septicemia after bone marrow graft. Arch Pediatr. 1995;2(3):245–8.PubMedCrossRefGoogle Scholar
  170. 170.
    de St Maurice A, Frangoul H, Coogan A, Williams JV. Prolonged fever and splenic lesions caused by Malassezia restricta in an immunocompromised patient. Pediatr Transplant. 2014;18(8):E283–6.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Viscomi SG, Mortele KJ, Cantisani V, Glickman J, Silverman SG. Fatal, complete splenic infarction and hepatic infection due to disseminated Trichosporon beigelii infection: CT findings. Abdom Imaging. 2004;29(2):228–30.PubMedCrossRefGoogle Scholar
  172. 172.
    Alegre A, Algora M, Penalver MA, Llanos ML, Perez-Pons C, Garcia Plaza I, et al. Focal hepato-splenic mycosis caused by Trichosporon beigelii in a patient with acute leukemia. Sangre. 1991;36(4):311–4.PubMedGoogle Scholar
  173. 173.
    Chen CY, Chen YC, Tang JL, Yao M, Huang SY, Tsai W, et al. Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. Ann Hematol. 2003;82(2):93–7.PubMedGoogle Scholar
  174. 174.
    von Eiff M, Essink M, Roos N, Hiddemann W, Buchner T, van de Loo J. Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies. Blut. 1990;60(4):242–8.CrossRefGoogle Scholar
  175. 175.
    Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol. 2002;71(4):260–7.PubMedCrossRefGoogle Scholar
  176. 176.
    Pagano L, Caira M, Fianchi L. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. Ann Med. 2005;37(4):259–69.PubMedCrossRefGoogle Scholar
  177. 177.
    Chagas-Neto TC, Chaves GM, Colombo AL. Update on the genus Trichosporon. Mycopathologia. 2008;166(3):121–32.PubMedCrossRefGoogle Scholar
  178. 178.
    Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis. 2004;36(8):564–9.PubMedCrossRefGoogle Scholar
  179. 179.
    Thompson 3rd GR, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother. 2009;64(1):79–83.PubMedCrossRefGoogle Scholar
  180. 180.
    Ikuta K, Torimoto Y, Yamamoto M, Okamura N, Hosoki T, Sato K, et al. Successful treatment of systemic Geotrichum capitatum infection by liposomal amphotericin-B, itraconazole, and voriconazole in a Japanese man. Intern Med. 2010;49(22):2499–503.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Jason A. Trubiano
    • 1
  • Sharon C.-A. Chen
    • 2
  • Monica A. Slavin
    • 1
  1. 1.Department of Infectious DiseasesPeter MacCallum Cancer CentreMelbourneAustralia
  2. 2.Department of Microbiology and Infectious DiseasesWestmead HospitalSydneyAustralia

Personalised recommendations